What Omeros Corporation’s OncotoX-AML study reveals about mutation-agnostic AML therapies
Omeros Corporation advances OncotoX-AML after primate data. Explore what this means for AML therapy, risks ahead, and why clinicians are watching closely.
Pharma & Biotech